Rocket Pharmaceuticals secures up to $150M credit facility from Hercules Capital; $35M drawn at close

ROCKET PHARMACEUTICALS, INC.

Credit facility with Hercules Capital provides up to $150M: $35M funded Sept 30, 2026; $20M and $15M available through mid-2027; $30M on Danon milestone; $50M subject to Hercules approval.
Interest at greater of prime or 6.75% plus 2.40%; interest-only through April 1, 2029, extendable to Oct 1, 2030 if FDA approves RP-A501 BLA for Danon disease; matures Oct 1, 2030.
Warrants issued to Lenders for up to 1,755,853 shares at $2.99/share; 409,699 exercisable after Tranche 1-A; fully exercisable only if $150M fully drawn.
Rocket had $283.7M cash as of June 30, 2026; with $35M initial draw, runway into Q3 2028; additional draws could extend into 2029.
Proceeds support pivotal Phase 2 study of RP-A501 for Danon disease and cardiovascular pipeline; CEO cites priority review voucher sale as diversifying capital.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.